Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2006 2
2007 3
2008 2
2009 1
2010 2
2013 3
2014 2
2015 6
2016 3
2017 7
2018 10
2019 9
2020 5
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ann o farrell[Author] (16 results)?
Gemtuzumab ozogamicin.
Przepiorka D, Deisseroth A, Kane R, Kaminskas E, Farrell AT, Pazdur R. Przepiorka D, et al. Among authors: farrell at. J Clin Oncol. 2013 May 1;31(13):1699-700. doi: 10.1200/JCO.2012.48.1887. Epub 2013 Mar 25. J Clin Oncol. 2013. PMID: 23530094 No abstract available.
FDA Approval: Blinatumomab.
Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R. Przepiorka D, et al. Among authors: farrell at. Clin Cancer Res. 2015 Sep 15;21(18):4035-9. doi: 10.1158/1078-0432.CCR-15-0612. Clin Cancer Res. 2015. PMID: 26374073
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G, Blumenthal GM, Amiri-Kordestani L, Singh H, Fashoyin-Aje L, Gormley N, Kluetz PG, Pazdur R, Beaver JA, Theoret MR. Chang E, et al. Among authors: farrell at. Oncologist. 2021 Oct;26(10):e1786-e1799. doi: 10.1002/onco.13887. Epub 2021 Jul 27. Oncologist. 2021. PMID: 34196068 Free PMC article. Review.
Oncology drug review process.
Farrell AT, Pazdur R. Farrell AT, et al. J Natl Compr Canc Netw. 2003 Jan;1(1):109-13. doi: 10.6004/jnccn.2003.0011. J Natl Compr Canc Netw. 2003. PMID: 19764154 Review.
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Kane RC, et al. Among authors: farrell at. Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Oncologist. 2009. PMID: 19144678 Free article. Review.
A strategic framework for novel drug development in multiple myeloma.
Anderson KC, Hannah AL, Pazdur R, Farrell AT. Anderson KC, et al. Among authors: farrell at. Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x. Br J Haematol. 2007. PMID: 17593022 Free article. Review. No abstract available.
Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Kane RC, et al. Among authors: farrell at. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249. Clin Cancer Res. 2006. PMID: 17189398 Review.
58 results